CPT1C and neoplasm: Moreover, poor disease-free survival (DFS; Figure 7F), progression-free survival (PFS; Figure 7G) as well as disease-specific survival (DSS; Figure 7H) were observed in the CPT1C-High cohort, indicating high CPT1C expression could predict unfavorable clinical outcomes in BLBC patients, and strongly suggesting a pivotal role of CPT1C in facilitating tumor progression in vivo.